Examination of Nociscan Impact on Discogenic Low Back Pain Surgical Outcomes

Last updated: April 23, 2025
Sponsor: Aclarion
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chronic Pain

Treatment

Fusion or TDR determined by investigator.

Clinical Study ID

NCT06661850
Clarity
  • Ages 18-70
  • All Genders

Study Summary

This study is looking into how safe and useful NOCISCAN is. NOCISCAN is a software as a Service (SaaS) tool that uses Magnetic Resonance (MR) spectroscopy. Nociscan (instead of 'It') leverages MRS to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The randomized controlled trial will compare the blinded and unblinded cohorts and their corresponding surgical outcomes with the Nocigram reports, generated prior to treatment, for each patient."

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Subject is a skeletally mature male or female (non-pregnant) aged 18 to 70 years (inclusive);

  2. Subject is plans to undergo surgical treatment of their discogenic back painindependent of this research protocol;

  3. Subject is to be treated with on-label use of FDA-cleared or FDA-approved devicesindependent of this research protocol;

  4. Subject has a primary diagnosis of discogenic back pain in up to two lumbar levelscaused by degenerative disc disease identified via MRI;

  5. Subject has a preoperative Oswestry Disability Questionnaire score ≥40 out of 100points (40/100);

  6. Subject has a VAS back pain score of ≥40mm and that is greater than the worst VASleg pain score;

  7. Subject has failed at least ≥ 6 months of non-operative treatment (for example:physical therapy, bed rest, anti-inflammatory or analgesic medications, chiropracticcare, acupuncture, massage therapy or home-directed lumbar exercise programs);

  8. Subject has signed the IRB approved Informed Consent Form; and

  9. Subject is psychosocially, mentally and physically able and willing to fully complywith this protocol including adhering to follow-up schedule and requirements andfilling out forms.

Exclusion

Exclusion Criteria:

  1. Subject has a primary diagnosis of spinal condition other than degenerative discdisease at the involved level (i.e., facet joint pain/SI pain);

  2. Subject has had prior lumbar back surgery or intradiscal treatments at any lumbarlevel (Note: diagnostic provocative or anesthetic discography are not excluded;micro-discectomy, decompression, or laminectomy patients greater than 6 monthspostop are not excluded);

  3. Surgery is planned for more than 2 lumbar levels.

  4. Subject has clinically significant spinal canal stenosis as assessed by theInvestigator;

  5. Subject has a motor strength deficit(s) in lower extremities

  6. Subject has a lumbar spine diagnosis, based on radiographic evidence, of clinicallyrelevant lumbar vertebral abnormalities (except Modic end-plate changes, which arenot excluded), including:

  • Spondylolisthesis with more than 2 mm of translation, or with pars fracture, atthe involved level

  • Spondylolysis

  • Lumbar scoliosis with a Cobb angle of greater than 15°

  • Evidence of prior fracture or trauma to the L1, L2, L3, L4, or L5 levels ineither compression or burst

  • Lumbar kyphosis

  1. Subject has radiologic evidence of lumbar disc herniation comprising extrusion

  2. Subject is contraindicated for a standard lumbar MRI exam

  3. Women who are currently pregnant (or believe they may be at risk of being orbecoming pregnant), or are breast feeding, during the study period when scans willbe performed

  4. Subject is currently receiving worker's compensation or is involved in in anylitigation for personal injury, medical negligence, trauma, or worker'scompensation.

  5. Subject has a chronic disease (other than degenerative disc disease), chronic pain (other than discogenic low back pain), or psychological dysfunction, which may, inthe opinion of the Principal Investigator, compromise a subject's ability to complywith study procedures, and/or may confound data

  6. Subject has a BMI > 40

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: Fusion or TDR determined by investigator.
Phase:
Study Start date:
May 01, 2025
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • Northwestern University

    Chicago, Illinois 60611
    United States

    Active - Recruiting

  • Advocate Aurora Research Institute

    Park Ridge, Illinois 60068
    United States

    Active - Recruiting

  • Texas Back Institute

    Plano, Texas 75093
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.